内部人交易记录
其他尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the detailed record of transactions filed by Levy Richard S. Officer active across 5 companies, notably Protara Therapeutics, Inc.. In total, 24 filings have been recorded. Split: 2 buys · 1 sell. Total volume traded: €114k. History available since 17 January 2023. The latest transaction was filed on 23 February 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Levy Richard S
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报24 总计
403 股Class A Ordinary ShareSEC:0001454983-26-000008:0
2,500 股@ US$7.360.8% 占其流量Common StockSEC:0001628280-26-011211:0
683 股Class A Ordinary ShareSEC:0001454983-26-000002:0
4,000 股@ US$16.462.8% 占其流量Common StockSEC:0001628280-26-003491:0
2,500 股@ US$7.360.8% 占其流量Common StockSEC:0001628280-25-052411:0
1,101 股Class A Ordinary ShareSEC:0001415889-25-019334:0
715 股0Common StockSEC:0001628280-25-032861:0
3,173 股Class A Ordinary ShareSEC:0001415889-25-015800:0
20,000 股@ US$3.1950.0% 占其流量Common StockSEC:0001213900-25-045399:0
20,000 股@ US$3.1950.0% 占其流量Common StockSEC:0001213900-25-044871:0
9,470 股@ US$65.0629.4% 占其流量Common StockSEC:0001628280-25-017563:0
1,303 股Class A Ordinary ShareSEC:0001415889-24-026617:0
5,000 股@ US$7.361.8% 占其流量Common StockSEC:0000950170-24-124232:0
5,000 股@ US$7.361.8% 占其流量Common StockSEC:0000950170-24-121722:0
714 股0Common StockSEC:0000950170-24-078749:0
4,373 股Class A Common ShareSEC:0001415889-24-016006:0
747 股Class A Common ShareSEC:0001415889-24-012480:0
5,000 股@ US$7.361.8% 占其流量Common StockSEC:0000950170-24-041528:0
2,777 股Class A Common ShareSEC:0001415889-23-014841:0
5,000 股Class A Common ShareSEC:0001415889-23-010562:0
1,198 股0Common StockSEC:0000899243-23-016060:0
12,489 股@ US$105.0865.1% 占其流量Common StockSEC:0000899243-23-002219:0
3,937 股Common StockSEC:0001209191-16-090542:0
3,937 股Common StockSEC:0001209191-16-090542:1
About Levy Richard S
Levy Richard S is a Director at Madrigal Pharmaceuticals, INC., Kiniksa Pharmaceuticals International, plc, Kiniksa Pharmaceuticals, Ltd. and Protara Therapeutics, Inc., and EVP, Chief Drug Dev Officer at INCYTE CORP. He has 23 filings in total, and across the recent filings available, buys amount to EUR 114113 and sells to EUR 0, with activity spanning from 2016-01-08 to 2026-02-24, the most common transaction nature being Levée d'options.